Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue.

Seidler M, Uckert S, Waldkirch E, Stief CG, Oelke M, Tsikas D, Sohn M, Jonas U.

Eur Urol. 2002 Nov;42(5):523-8.

PMID:
12429164
2.

Effects of NCX 4050, a new NO donor, in rabbit and human corpus cavernosum.

Filippi S, Crescioli C, Vannelli GB, Fazzini A, Natali A, Riffaud JP, Maggi M, Ledda F.

Int J Androl. 2003 Apr;26(2):101-8.

PMID:
12641828
3.

Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro.

Machtens S, Ckert S, Stief CG, Tsikas D, Frlich Jr, Jonas U.

Urology. 2003 Feb;61(2):479-83.

PMID:
12597985
4.
5.

Effects of various nitric oxide donating agents on the contractility and cyclic nucleotide turnover of human seminal vesicles in vitro.

Heuer O, Uckert S, Machtens SA, Stief CG, Tsikas D, Frölich JC, Jonas U.

Urology. 2002 Jun;59(6):958-62.

PMID:
12031394
6.

The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit.

Thompson CS, Mumtaz FH, Khan MA, Wallis RM, Mikhailidis DP, Morgan RJ, Angelini GD, Jeremy JY.

Eur J Pharmacol. 2001 Aug 3;425(1):57-64.

PMID:
11672575
7.
8.
9.

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.

Saenz de Tejada I, Angulo J, Cuevas P, Fernández A, Moncada I, Allona A, Lledó E, Körschen HG, Niewöhner U, Haning H, Pages E, Bischoff E.

Int J Impot Res. 2001 Oct;13(5):282-90.

PMID:
11890515
10.
11.

[In vitro effects of a novel class of nitric oxide donating compounds on isolated human urinary bladder].

Kedia GT, Neumayer E, Scheller F, Kuczyk MA, Uckert S.

Georgian Med News. 2009 Feb;(167):7-16. German.

PMID:
19276460
12.

Comparative effects of sildenafil, phentolamine, yohimbine and L-arginine on the rabbit corpus cavernosum.

Sharabi FM, Daabees TT, El-Metwally MA, Senbel AM.

Fundam Clin Pharmacol. 2004 Apr;18(2):187-94.

PMID:
15066133
13.

Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum.

Gur S, Kadowitz PJ, Trost L, Hellstrom WJ.

J Urol. 2007 Oct;178(4 Pt 1):1543-8.

PMID:
17707054
14.

Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway.

McAuley IW, Kim NN, Min K, Goldstein I, Traish AM.

J Androl. 2001 Jul-Aug;22(4):623-8.

16.

[In vitro effects of cAMP- and cGMP-stimulating drugs on the relaxation of the prostate smooth muscle tissue contraction induced by endothelin-1].

Kediia G, Uckert S, Kediia M, Truss MC, Chigogidze T, Jonas U, Managadze LG.

Georgian Med News. 2006 Feb;(131):7-13. Russian.

PMID:
16575120
17.

Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.

Moreland RB, Goldstein I, Traish A.

Life Sci. 1998;62(20):PL 309-18.

PMID:
9600334
18.
19.

Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum.

Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G.

Eur J Pharmacol. 2008 Sep 4;591(1-3):189-95. doi: 10.1016/j.ejphar.2008.06.055.

PMID:
18593576
20.

Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue.

Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, Jonas U.

Urology. 2000 Jan;55(1):146-50.

PMID:
10654914

Supplemental Content

Support Center